- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01686451
The Effect of XueZhiKang on Fatigue:Comparing With Simvastatin
Comparison Between XueZhiKang and Simvastatin on Fatigue: a Single-center, Randomized Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Individuals at risk for cardiovascular disease (CVD) are often prescribed statins, which are medications that reduce the amount of cholesterol in the blood. By lowering cholesterol levels, these individuals have a lower incidence of coronary artery disease, ischemic stroke, and peripheral arterial disease and so on. While statins are effective at lowering cholesterol levels, their effect on fatigue is obvious and has been suggested by several studies, including one randomized, double-blind, placebo-controlled clinical trial. And XueZhiKang may be not. The purpose of this study is to compare the effect of these two medications on fatigue in persons who are at moderate to low CVD risk based on the risk estimation system in ESC(European Society of Cardiology)/ESA(European Atherosclerosis Society) guidelines (2011) for the management of dyslipidemias.
This study will enroll individuals who do not currently take cholesterol-lowering medications. Participants will be randomly assigned to receive 600mg of XueZhiKang twice a day, or 20mg of simvastatin daily for 4 weeks. Study visits will occur at baseline and Week 4. Blood will be collected for laboratory testing, and standardized psychological questionnaires will assess fatigue scores and physical activity levels at baseline and week 4. Pill count will be used to assess adherence of XueZhiKang and simvastatin treatment at week 4. At week 4, medication side effects will be monitored and tests of alanine aminotransferase (ALT), aspartate aminotransaminase (AST) and creatine phosphate kinase (CPK) will be performed. At week 4, medication efficacy will be assessed and test of low-density lipoprotein cholesterol (LDL-C) will be performed.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Zhejiang
-
Wenzhou, Zhejiang, China, 325000
- Second Hispital of Wenzhou Medical University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- LDL cholesterol level between 115-190 mg/dL;
- Able to fast prior to blood draw;
- Able to comfortably read and write in Chinese;
- Able and willing to refrain from donating whole blood during study participation;
- Willing to abstain from consuming large amounts of grapefruit juice.
Exclusion Criteria:
- Current use of lipid-lowering medications;
- Documented cardiovascular disease (CVD) by invasive or non-invasive testing (such as coronary angiography, nuclear imaging, stress echocardiography, carotid plaque on ultrasound), previous myocardial infarction (MI), acute coronary syndrome (ACS), coronary revascularization [percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG)] and other arterial revascularization procedures, ischaemic stroke, peripheral arterial disease(PAD);
- Patients with type 2 diabetes, patients with type 1 diabetes with target organ damage (such as microalbuminuria);
- Patients with moderate to severe chronic kidney disease [glomerular filtration rate (GFR) < 60 mL/min/1.73㎡];
- Markedly elevated single risk factors such as familial dyslipidaemias and severe hypertension;
- A calculated SCORE ≥5% for 10 year risk of fatal CVD;
- Cancer;
- HIV infected;
- Medical or psychiatric condition that prevents full study participation or follow-up (e.g., active psychosis);
- Active liver disease or unexplained persistent elevated transaminase levels;
- Major surgery or hospitalization in the 3 months prior to study entry;
- Current use of cyclosporin, erythromycin, clarithromycin, nefazodone, or any "azole" antifungals, including fluconazole, itraconazole, ketoconazole, mibefradil, or protease inhibitors;
- Female of childbearing potential;
- Current participation in another clinical trial.
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: XueZhiKang
Participants will receive 600mg of XueZhiKang twice a day for 4 weeks.
|
Participants will receive 600mg of XueZhiKang twice a day for 4 weeks.
|
Active Comparator: Simvastatin
Participants will receive 20mg of simvastatin daily for 4 weeks.
|
Participants will receive 20mg of simvastatin daily for 4 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison Between XueZhiKang and Simvastatin on Fatigue Scores
Time Frame: Measured at baseline and week 4
|
At baseline and week 4, the fatigue score was assessed by a fatigue questionnaire named as Fatigue Assessment Scale (FAS) which used 10-item fatigue measure with the fatigue score ranged from 10-50.
The higher score was meaning of higher level of fatigue.
|
Measured at baseline and week 4
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment Efficacy
Time Frame: Measured at baseline and week 4
|
Treatment efficacy was estimated on the basis of triglyceride (TG), total cholesterol (TC), high-density lipoprotein-cholesterol (HDL-C), as well as LDL-C levels obtained at baseline and week 4.
|
Measured at baseline and week 4
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of XueZhiKang With Simvastatin of Physical Activity Level
Time Frame: Measured at baseline and week 4
|
At baseline and week 4, we estimated physical activity level by short version of international physical activity questionnaire (IPAQ) with categorical score ranged from low to high.
The higher score was meaning of lower physical activity level.
|
Measured at baseline and week 4
|
Comparison of Safety Laboratory Testings (ALT,AST,CPK) Between Simvastatin- and Xuezhikang-groups
Time Frame: Measured at baseline and week 4
|
Fasting blood samples were collected at weeks 0 (randomization) and 4 (end of study) for clinical chemistry.
|
Measured at baseline and week 4
|
Comparison of Safety Laboratory Testing (Cr) Between Simvastatin- and Xuezhikang-group
Time Frame: Measured at baseline and week 4
|
Fasting blood samples were collected at weeks 0 (randomization) and 4 (end of study) for clinical chemistry.
|
Measured at baseline and week 4
|
Treatment Adherence at Week 4 in Simvastatin- and Xuezhikang-group
Time Frame: Measured at baseline and week 4
|
We counted the total number of pills that were dispensed to the participants at baseline and the total number of pills that were taken by participants at week 4.
|
Measured at baseline and week 4
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Wenzhou
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dyslipidemias
-
IlDong Pharmaceutical Co LtdCompletedMixed DyslipidemiasKorea, Republic of
-
Orient Pharma Co., Ltd.CompletedPrimary Hypercholesterolemia | Mixed DyslipidemiasTaiwan, Australia, New Zealand
-
Yonsei UniversityRecruitingClinical Trial to Evaluate the Efficacy and Safety of Suvaro®OD Tablet in Patients With DyslipidemiaDyslipidemiaKorea, Republic of
-
Dongkwang Pharm. Co., Ltd.Not yet recruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingDyslipidemias
-
Hospices Civils de LyonRecruiting
-
AstraZenecaAstraZeneca K.K.Active, not recruitingDyslipidemiaCzechia, United States, Slovakia, Japan, Canada, Spain, Hungary, Denmark
-
Chong Kun Dang PharmaceuticalCompletedDyslipidemiasKorea, Republic of
-
AmgenCompletedDyslipidemiaUnited States, Poland, Czechia, Hungary, Russian Federation, Ukraine, Slovakia
Clinical Trials on XueZhiKang
-
China Academy of Chinese Medical SciencesCompleted
-
Beijing Peking University WBL Biotech Co., Ltd.CompletedHyperlipidemiaChina, United States
-
Chinese Academy of Medical Sciences, Fuwai HospitalPeking University First Hospital; Peking Union Medical College Hospital; Beijing...Unknown
-
Luye Pharma Group Ltd.CompletedLipid Metabolism DisorderUnited States
-
Heart Health Research CenterAstraZenecaCompletedMetabolism Disorder, Glucose | Metabolism Disorder, LipidChina
-
Wenzhou Medical UniversityRecruitingAtherosclerosis | DyslipidemiaChina